Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY® (aripiprazole) Injection, an injectable ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...

Oct. 25, 2005 (Toronto) — Children and adolescents with schizophrenia, bipolar disorder, and other severe psychiatric diagnoses improved significantly when treated with aripiprazole (Abilify) and ...

A long-acting, injectable form of the antipsychotic drug aripiprazole (Abilify, Otsuka) given once a month provides a safe and effective means of maintenance therapy for the treatment of bipolar I ...

Abilify Asimtufii (aripiprazole) is prescribed to help treat schizophrenia and bipolar I disorder. The drug comes as a suspension (a liquid mixture) that a healthcare professional injects into a ...

Dosage for Abilify (aripiprazole) may vary based on the condition it’s being used to treat. Your doctor may adjust your dosing of Abilify over the course of your treatment. The active ingredient in ...

PRINCETON, NJ and TOKYO, JAPAN, November 20, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...

The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...

The evidence base for the prescribing of aripiprazole in maintenance treatment of bipolar disorder is limited to a single trial, sponsored by the manufacturer of aripiprazole, according to a rigorous ...